Your browser doesn't support javascript.
loading
Meta-analysis of Genetic Modifiers Reveals Candidate Dysregulated Pathways in Amyotrophic Lateral Sclerosis.
Yanagi, Katherine S; Wu, Zhijin; Amaya, Joshua; Chapkis, Natalie; Duffy, Amanda M; Hajdarovic, Kaitlyn H; Held, Aaron; Mathur, Arjun D; Russo, Kathryn; Ryan, Veronica H; Steinert, Beatrice L; Whitt, Joshua P; Fallon, Justin R; Fawzi, Nicolas L; Lipscombe, Diane; Reenan, Robert A; Wharton, Kristi A; Hart, Anne C.
Afiliação
  • Yanagi KS; Neuroscience Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Katherine_Yanagi@brown.edu.
  • Wu Z; Department of Biostatistics, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Zhijin_Wu@brown.edu.
  • Amaya J; Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Joshua_Amaya@alumni.br
  • Chapkis N; Department of Neuroscience, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Natalie_Chapkis@alumni.brown.edu.
  • Duffy AM; Neuroscience Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Amanda_Duffy@alumni.brown.edu.
  • Hajdarovic KH; Neuroscience Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Kaityln_Hajdarovic@brown.edu.
  • Held A; Molecular Biology, Cell Biology, and Biochemistry Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Aaron_Held@brown.edu.
  • Mathur AD; Molecular Biology, Cell Biology, and Biochemistry Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Arjun_Mathur@brown.edu.
  • Russo K; Neuroscience Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Kathryn_Russo@brown.edu.
  • Ryan VH; Neuroscience Graduate Program, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Veronica_Ryan@brown.edu.
  • Steinert BL; Molecular Biology, Cell Biology, and Biochemistry Department, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: bsteinert@g.harvard.edu.
  • Whitt JP; Department of Neuroscience, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Joshua_Whitt@brown.edu.
  • Fallon JR; Department of Neuroscience, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Justin_Fallon@brown.edu.
  • Fawzi NL; Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Nicolas_Fawzi@brown.ed
  • Lipscombe D; Department of Neuroscience, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Diane_Lipscombe@brown.edu.
  • Reenan RA; Molecular Biology, Cell Biology, and Biochemistry Department, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Robert_Reenan@brown.edu.
  • Wharton KA; Molecular Biology, Cell Biology, and Biochemistry Department, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Kristi_Wharton@brown.edu.
  • Hart AC; Department of Neuroscience, Brown University, Providence, Rhode Island 02912, United States; Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, Rhode Island 02912, United States. Electronic address: Anne_Hart@brown.edu.
Neuroscience ; 396: A3-A20, 2019 01 01.
Article em En | MEDLINE | ID: mdl-30594291
ABSTRACT
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that has significant overlap with frontotemporal dementia (FTD). Mutations in specific genes have been identified that can cause and/or predispose patients to ALS. However, the clinical variability seen in ALS patients suggests that additional genes impact pathology, susceptibility, severity, and/or progression of the disease. To identify molecular pathways involved in ALS, we undertook a meta-analysis of published genetic modifiers both in patients and in model organisms, and undertook bioinformatic pathway analysis. From 72 published studies, we generated a list of 946 genes whose perturbation (1) impacted ALS in patient populations, (2) altered defects in laboratory models, or (3) modified defects caused by ALS gene ortholog loss of function. Herein, these are all called modifier genes. We found 727 modifier genes that encode proteins with human orthologs. Of these, 43 modifier genes were identified as modifiers of more than one ALS gene/model, consistent with the hypothesis that shared genes and pathways may underlie ALS. Further, we used a gene ontology-based bioinformatic analysis to identify pathways and associated genes that may be important in ALS. To our knowledge this is the first comprehensive survey of ALS modifier genes. This work suggests that shared molecular mechanisms may underlie pathology caused by different ALS disease genes. Surprisingly, few ALS modifier genes have been tested in more than one disease model. Understanding genes that modify ALS-associated defects will help to elucidate the molecular pathways that underlie ALS and provide additional targets for therapeutic intervention.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Genes Modificadores / Esclerose Lateral Amiotrófica Tipo de estudo: Systematic_reviews Limite: Animals / Humans Idioma: En Revista: Neuroscience Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Genes Modificadores / Esclerose Lateral Amiotrófica Tipo de estudo: Systematic_reviews Limite: Animals / Humans Idioma: En Revista: Neuroscience Ano de publicação: 2019 Tipo de documento: Article